WHG
VERV

Westwood Holdings Group’s Verve Therapeutics VERV Stock Holding History

Westwood Holdings Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,097
Closed -$293K – 513
2025
Q2 		$293K Hold
26,097
– – ﹤0.01% 448
2025
Q1 		$119K Hold
26,097
– – ﹤0.01% 459
2024
Q4 		$147K Hold
26,097
– – ﹤0.01% 481
2024
Q3 		$126K Hold
26,097
– – ﹤0.01% 467
2024
Q2 		$127K Hold
26,097
– – ﹤0.01% 449
2024
Q1 		$347K Hold
26,097
– – ﹤0.01% 418
2023
Q4 		$364K Hold
26,097
– – ﹤0.01% 410
2023
Q3 		$346K Sell
26,097
-7,254
-22% -$117K ﹤0.01% 403
2023
Q2 		$625K Sell
33,351
-525
-2% -$8.74K 0.01% 374
2023
Q1 		$488K Buy
33,876
+7,779
+30% +$152K ﹤0.01% 396
2022
Q4 		$505K Hold
26,097
– – ﹤0.01% 400
2022
Q3 		$896K Hold
26,097
– – 0.01% 326
2022
Q2 		$399K Buy
26,097
+17,024
+188% +$264K ﹤0.01% 404
2022
Q1 		$207K Buy
+9,073
New +$259K ﹤0.01% 446

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Westwood Holdings Group's VERV Position: Q3 2025 in Review

Westwood Holdings Group sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 26,097 shares — an estimated $293K sold.

Westwood Holdings Group first reported a position in VERV in Q1 2022 and held it in 14 quarters. The position peaked at $896K in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Westwood Holdings Group reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Westwood Holdings Group sold 26,097 Verve Therapeutics shares in Q3 2025, an estimated $293K.
  • Westwood Holdings Group first reported a position in Verve Therapeutics in Q1 2022 and held it in 14 quarters.
  • Westwood Holdings Group's Verve Therapeutics position peaked at $896K in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Westwood Holdings Group's 13F filing for Q3 2025, filed 14 Nov 2025.